Sandoz Rolls Out Natalizumab Biosimilar In Germany
Tyruko Version Of Natalizumab Will Rival Biogen’s Tysabri In A Major EU Market
Executive Summary
Sandoz is rolling out its Tyruko natalizumab biosimilar rival to Biogen’s Tysabri in Germany, heralding the product as the “first and only biosimilar for multiple sclerosis.”